{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/incontinence-urinary-in-women/prescribing-information/mirabegron/","result":{"pageContext":{"chapter":{"id":"2e7111be-d25f-52ec-9f6b-2aaea7583699","slug":"mirabegron","fullItemName":"Mirabegron","depth":2,"htmlHeader":"<!-- begin field d3cf7689-2381-463c-b4b0-cbde8eb61f6b --><h2>Mirabegron</h2><!-- end field d3cf7689-2381-463c-b4b0-cbde8eb61f6b -->","summary":"","htmlStringContent":"<!-- begin item aa517997-7912-4f3f-8f31-6567a993c72f --><!-- end item aa517997-7912-4f3f-8f31-6567a993c72f -->","topic":{"id":"c16535c5-1fa2-5d4a-a89f-9863872fca0e","topicId":"9e411d60-4060-4d95-8511-0998688cea47","topicName":"Incontinence - urinary, in women","slug":"incontinence-urinary-in-women","lastRevised":"Last revised in October 2019","chapters":[{"id":"592d340e-2c89-5e8e-9781-8398ef51af2c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"93b3be44-57e0-59a2-b936-4b447f0b2961","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"c15069c4-b8dd-5092-9861-e20a636b9367","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"3dc5fefe-1cf0-54d7-92d3-e1c0c60c6fb9","slug":"changes","fullItemName":"Changes"},{"id":"fb9741e6-b4f0-5ec2-ada2-a14af327feed","slug":"update","fullItemName":"Update"}]},{"id":"1ae974b5-487a-5fdf-88b5-6d9ed1e83525","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"399a4681-e92c-5e84-a738-fded957e135f","slug":"goals","fullItemName":"Goals"},{"id":"6507910a-37cb-51a9-8d3d-b69725293a87","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"9cd9dcb7-4d7b-5d3b-aa75-6fb40bf5928b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f79e3765-8adb-5e3f-b68f-48aa4ddeb34b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e1ab1bca-96c7-5187-894e-1e1fe32f92d6","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"97c63b91-f53e-5694-b807-0899dd34d53a","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0c2e43fc-1afb-59f4-8819-0ff5edc09eeb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"3ab1ad04-1d9d-52bc-b4c9-ad0787598df3","slug":"definition","fullItemName":"Definition"},{"id":"a9c53f9f-2962-5eb2-8cae-91fc90a5a1f4","slug":"causes-contributing-factors","fullItemName":"Causes and contributing factors"},{"id":"4bbda54d-1a4f-591c-8463-082fcdf61d7c","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e79a0901-9992-5f45-8cf5-c15ce06b5deb","slug":"complications","fullItemName":"Complications"},{"id":"b70db9b0-ddc3-5b42-888e-7171189f4ee5","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"a84e9562-3c9c-5c5e-8832-06e65a89aa2f","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"49f48003-2f49-51d5-acfe-7ba0fcff8fae","slug":"assessment-overview","fullItemName":"Assessment overview"},{"id":"060afa31-1619-5a1a-a7e5-bcb583129aca","slug":"assessing-the-type-of-urinary-incontinence","fullItemName":"Assessing the type of urinary incontinence"},{"id":"9897aa86-8c09-5550-8496-da8cb12787bf","slug":"assessing-for-underlying-causes-contributing-factors","fullItemName":"Assessing for underlying causes and contributing factors"},{"id":"49079af0-34b2-5cab-9135-40f57ee1eea4","slug":"assessing-for-complications","fullItemName":"Assessing for complications"},{"id":"c9c5f464-0433-5027-a22c-8d2b8fb239bd","slug":"assessing-the-severity-of-urinary-incontinence","fullItemName":"Assessing the severity of urinary incontinence"}]},{"id":"a7454b90-f574-597a-b3ce-8f0b3967e058","fullItemName":"Management","slug":"management","subChapters":[{"id":"26043de5-bad9-57d7-abad-98942e3ed62c","slug":"managing-stress-incontinence","fullItemName":"Scenario: Managing stress incontinence"},{"id":"280a972f-ec97-53b4-ab56-b67df1df40d3","slug":"managing-urgency-incontinence","fullItemName":"Scenario: Managing urgency incontinence"},{"id":"dff61990-c7a9-5600-b15a-e9098f480b65","slug":"managing-mixed-urinary-incontinence","fullItemName":"Scenario: Managing mixed urinary incontinence"},{"id":"4e21298e-b75d-5104-9b4b-a9817cb8d9b6","slug":"managing-overflow-urinary-incontinence","fullItemName":"Scenario: Managing overflow urinary incontinence"},{"id":"d5ace44e-cc5a-5618-bb48-24058af84ec8","slug":"managing-a-urogenital-fistula","fullItemName":"Scenario: Managing a urogenital fistula"}]},{"id":"d814319d-0309-591f-aa84-5dfa4933d33b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"3d2d4594-7f5e-5ad4-9537-22965cd3859f","slug":"antimuscarinics","fullItemName":"Antimuscarinics"},{"id":"c57e795e-2c4a-5f04-83ae-289890ef29ea","slug":"desmopressin","fullItemName":"Desmopressin"},{"id":"2bf52d86-2720-51b1-9411-89ebb7ff9b07","slug":"duloxetine","fullItemName":"Duloxetine"},{"id":"7f2a8cea-ac55-5ac4-a58a-52dbe5d19228","slug":"intravaginal-oestrogen","fullItemName":"Intravaginal oestrogen"},{"id":"2e7111be-d25f-52ec-9f6b-2aaea7583699","slug":"mirabegron","fullItemName":"Mirabegron"}]},{"id":"3ef95f2d-4da4-5002-9243-64779078fc11","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"bdb709b8-1321-594d-b446-51244a4b8f41","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"6ce87fd7-7343-5da1-b9a5-0035a5703c2c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3fe3b863-a1f0-5938-9f0d-bb718d670d28","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"947b96f3-7dc6-5136-96f6-431519b4646a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"16662eed-08e1-5333-85c0-65d2e4722f09","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"9c5908f0-10fa-5d1c-8762-8a682a1ee2c8","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"532bc548-9f39-5742-9a38-cb92893a8407","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d814319d-0309-591f-aa84-5dfa4933d33b","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"2709667b-3cdd-5f26-b8a6-a5d77a5bf73b","slug":"contraindications","fullItemName":"Contraindications","depth":3,"htmlHeader":"<!-- begin field 1ee07998-860f-459c-b72f-eafb26b085d6 --><h3>Contraindications</h3><!-- end field 1ee07998-860f-459c-b72f-eafb26b085d6 -->","summary":"","htmlStringContent":"<!-- begin item 6d37b654-e0ab-4504-9567-c6b7c49d716a --><!-- begin field 44e84d8f-6bf7-473d-8ac9-d62f3e2fd5d2 --><ul><li><strong>Do not prescribe mirabegron to people with: </strong><ul><li>Severe uncontrolled hypertension (systolic blood pressure 180 mmHg or higher, or diastolic blood pressure 110 mmHg or higher).</li><li>Severe hepatic impairment.</li><li>End stage renal disease. </li></ul></li></ul><ul><li><strong>Prescribe mirabegron with caution to people with: </strong><ul><li>A history of QT interval prolongation.</li><li>Bladder outflow obstruction.</li><li>Hypertension (if systolic blood pressure 160 mm Hg or higher, or diastolic blood pressure is 100 mm Hg or higher).</li><li>Moderate hepatic impairment — reduce dose to 25 mg once daily.</li><li>Severe renal impairment — reduce dose to 25 mg once daily if eGFR 15–29 mL/minute/ 1.73 m<sup>2</sup>. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2019k</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 44e84d8f-6bf7-473d-8ac9-d62f3e2fd5d2 --><!-- end item 6d37b654-e0ab-4504-9567-c6b7c49d716a -->","subChapters":[]},{"id":"bdc59825-1b28-55b6-ac37-2534ba29af61","slug":"initiation-titration","fullItemName":"Initiation and titration","depth":3,"htmlHeader":"<!-- begin field 1cd1fc35-200f-460d-8fff-6071b8041480 --><h3>How should I start and titrate mirabegron</h3><!-- end field 1cd1fc35-200f-460d-8fff-6071b8041480 -->","summary":"","htmlStringContent":"<!-- begin item c256fee8-f5f5-44cb-bbf8-804009d3f8de --><!-- begin field 65576525-7b4a-49da-ac06-bcc3ba3519c3 --><ul><li><strong>Start at a dose of 50 mg once daily.</strong></li><li><strong>Start at a reduced dose of 25 mg once a day for people with:</strong><ul><li>Moderate hepatic impairment (avoid if the person is also taking a potent CYP3A4 inhibitor).</li><li>Mild hepatic impairment who are also taking a strong CYP3A4 inhibitor such as clarithromycin, itraconazole, or ritonavir.</li><li>Renal impairment — estimated glomerular filtration rate (eGFR) 15–29 mL/minute/1.73 m<sup>2</sup>.</li><li>Renal impairment — eGFR 30–89 mL/minute/1.73 m<sup>2</sup> — who are also taking a strong CYP3A4 inhibitor such as clarithromycin, itraconazole, or ritonavir.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI Medicines Compendium, 2014b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">BNF 68, 2014</a>]</p><!-- end field 65576525-7b4a-49da-ac06-bcc3ba3519c3 --><!-- end item c256fee8-f5f5-44cb-bbf8-804009d3f8de -->","subChapters":[]},{"id":"27554d2d-2c10-5773-8240-7b11fbbd660e","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 58bf89f0-6540-4e84-adc3-2f173fb05428 --><h3>What key drug interactions with mirabegron should I be aware of?</h3><!-- end field 58bf89f0-6540-4e84-adc3-2f173fb05428 -->","summary":"","htmlStringContent":"<!-- begin item fc0c4d0f-3eab-4453-acc4-b6465aa23265 --><!-- begin field 66d56c8c-852d-447e-a9b0-86a2df8a7d8c --><ul><li><strong>Strong CYP3A inhibitors such as clarithromycin, itraconazole, or ritonavir </strong>— avoid or reduce the dose of mirabegron in people with hepatic or renal impairment who are also taking one of these drugs. Plasma concentrations of mirabegron may be increased by concurrent use with strong CYP3A inhibitors.</li><li><strong>Mirabegron may increase the levels of some drugs if taken concurrently, including: </strong><ul><li>Beta blockers (metoprolol).</li><li>Colchicine.</li><li>Dabigatran.</li><li>Digoxin. </li><li>Everolimus, sirolimus.</li><li>Fexofenadine.</li><li>Loperamide. </li><li>Tricyclic antidepressants (for example imipramine).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2019k</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 66d56c8c-852d-447e-a9b0-86a2df8a7d8c --><!-- end item fc0c4d0f-3eab-4453-acc4-b6465aa23265 -->","subChapters":[]},{"id":"3afc806b-042b-5535-b4fc-f6537c3feb13","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 59711d50-d1fe-46fc-b169-fb5a9e1b254b --><h3>What adverse effects of mirabegron should I be aware of?</h3><!-- end field 59711d50-d1fe-46fc-b169-fb5a9e1b254b -->","summary":"","htmlStringContent":"<!-- begin item 72becd29-b9d6-4f0b-ba2b-814da7a7adb6 --><!-- begin field 526ef421-de23-4c69-8481-da7517150de2 --><ul><li><strong>Common adverse effects include:</strong><ul><li>Urinary tract infection.</li><li>Headache, dizziness.</li><li>Tachycardia.</li><li>Nausea, constipation, diarrhoea.</li></ul></li></ul><ul><li><strong>Other uncommon or rare adverse effects include:</strong><ul><li>Angioedema, pruritus, urticaria, rash.</li><li>Atrial fibrillation, palpitation.</li><li>Dyspepsia, gastritis.</li><li>Hypertensive crisis.</li><li>Joint swelling.</li><li>Vaginal infection, cystitis.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">ABPI, 2019k</a>]</p><!-- end field 526ef421-de23-4c69-8481-da7517150de2 --><!-- end item 72becd29-b9d6-4f0b-ba2b-814da7a7adb6 -->","subChapters":[]},{"id":"3a9fb8da-4b7f-5dde-9163-c40324df3046","slug":"monitoring","fullItemName":"Monitoring","depth":3,"htmlHeader":"<!-- begin field c04216da-65a9-46a4-8876-aadc00c9880d --><h3>What monitoring is required for mirabegron?</h3><!-- end field c04216da-65a9-46a4-8876-aadc00c9880d -->","summary":"","htmlStringContent":"<!-- begin item 35158337-7b2e-4de4-8170-aadc00c987de --><!-- begin field d96b4c5f-f430-49ae-ad2b-aadc00c9880d --><ul><li>Monitor blood pressure before starting treatment and regularly during treatment, especially in people with pre-existing hypertension.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/incontinence-urinary-in-women/references/\">Joint Formulary Committee, 2019</a>] </p><!-- end field d96b4c5f-f430-49ae-ad2b-aadc00c9880d --><!-- end item 35158337-7b2e-4de4-8170-aadc00c987de -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}